|
rs147001633
|
|
Leukemogenesis
|
|
0.030 |
GeneticVariation
|
BEFREE |
The R882H mutation causes a reduction in DNA methyltransferase activity and hypomethylation at differentially-methylated regions within the genome, ultimately preventing hematopoietic stem cell differentiation and leading to leukemogenesis.
|
31582562 |
2019 |
|
rs147001633
|
|
Leukemogenesis
|
|
0.030 |
GeneticVariation
|
BEFREE |
Molecularly, both DNMT3A-WT and R882H/C mutants interacted with PRDX2; and R882C/H mutation-induced hypomethylation increased PRDX2 expression which enhanced cell proliferation and growth with impairment of apoptosis, thereby contributing to leukemogenesis.
|
30245403 |
2018 |
|
rs147001633
|
|
Leukemogenesis
|
|
0.030 |
GeneticVariation
|
BEFREE |
Moreover, DNMT3A-R882H increased the CDK1 protein level and enhanced cell-cycle activity, thereby contributing to leukemogenesis.
|
24497509 |
2014 |
|
rs121913237
|
|
Leukemogenesis
|
|
0.020 |
GeneticVariation
|
BEFREE |
Cooperation of Dnmt3a R878H with Nras G12D promotes leukemogenesis in knock-in mice: a pilot study.
|
31703632 |
2019 |
|
rs121913237
|
|
Leukemogenesis
|
|
0.020 |
GeneticVariation
|
BEFREE |
It is thus unclear how Nras(G12D/+) signaling promotes leukemogenesis.
|
23687087 |
2013 |
|
rs387907272
|
|
Leukemogenesis
|
|
0.020 |
GeneticVariation
|
BEFREE |
Genetically, PA-DLBCL harbored a high prevalence of MYD88 L265P (24%) and CD79B mutations (52%) which may be involved in lymphomagenesis.
|
31609782 |
2020 |
|
rs387907272
|
|
Leukemogenesis
|
|
0.020 |
GeneticVariation
|
BEFREE |
In order to evaluate whether the presence of the recently described MYD88 L265P mutation in patients with Waldenström's macroglobulinemia (WM) is contributory to SS-associated lymphomagenesis, a quantitative allele-specific PCR method was performed in peripheral blood derived from 90 SS patients as well as in minor salivary gland tissues derived from 12 primary SS patients with or without lymphoma.
|
24153350 |
2014 |
|
rs10251201
|
|
Leukemogenesis
|
|
0.010 |
GeneticVariation
|
BEFREE |
The locus of rs974120 shows marks of transcriptional activity in leukemia according to ENCODE data. rs10251201 (7p21.3), rs9318227 (13q22.1), and rs10405859 (19q13.32) were associated with markers related to leukemogenesis and immune and inflammatory responses.
|
28375557 |
2017 |
|
rs10405859
|
|
Leukemogenesis
|
|
0.010 |
GeneticVariation
|
BEFREE |
The locus of rs974120 shows marks of transcriptional activity in leukemia according to ENCODE data. rs10251201 (7p21.3), rs9318227 (13q22.1), and rs10405859 (19q13.32) were associated with markers related to leukemogenesis and immune and inflammatory responses.
|
28375557 |
2017 |
|
rs1190999960
|
|
Leukemogenesis
|
|
0.010 |
GeneticVariation
|
BEFREE |
In contrast, p27 mutations that enhance its stability (p27(T187A)) or nuclear retention (p27(S10A)) attenuate leukemogenesis over wild-type p27, validating the tumor-suppressor function of nuclear p27 in CML.
|
25293778 |
2014 |
|
rs1217007648
|
|
Leukemogenesis
|
|
0.010 |
GeneticVariation
|
BEFREE |
Transcription activator-like effector nuclease-based knock-in mutagenesis provides evidence from a B lymphoid context that K171E IKKβ contributes to lymphomagenesis.
|
25107905 |
2014 |
|
rs121912472
|
|
Leukemogenesis
|
|
0.010 |
GeneticVariation
|
BEFREE |
Thus our studies provide clues in understanding the leukemogenesis of JAK2 K607N mutation in AML.
|
30521925 |
2019 |
|
rs121913459
|
|
Leukemogenesis
|
|
0.010 |
GeneticVariation
|
BEFREE |
Furthermore, pharmacologic doses of FTY720 remarkably suppress in vivo p210/p190(BCR/ABL)-driven [including p210/p190(BCR/ABL)(T315I)] leukemogenesis without exerting any toxicity.
|
17717597 |
2007 |
|
rs121913514
|
|
Leukemogenesis
|
|
0.010 |
GeneticVariation
|
BEFREE |
The t(8;21) Acute Myeloid Leukaemia (AML) Kasumi-1 cell line with N822K KIT mutation, is a model system for leukemogenesis.
|
20227111 |
2010 |
|
rs1250394819
|
|
Leukemogenesis
|
|
0.010 |
GeneticVariation
|
BEFREE |
In contrast, p27 mutations that enhance its stability (p27(T187A)) or nuclear retention (p27(S10A)) attenuate leukemogenesis over wild-type p27, validating the tumor-suppressor function of nuclear p27 in CML.
|
25293778 |
2014 |
|
rs1483790387
|
|
Leukemogenesis
|
|
0.010 |
GeneticVariation
|
BEFREE |
In contrast, p27 mutations that enhance its stability (p27(T187A)) or nuclear retention (p27(S10A)) attenuate leukemogenesis over wild-type p27, validating the tumor-suppressor function of nuclear p27 in CML.
|
25293778 |
2014 |
|
rs2239630
|
|
Leukemogenesis
|
|
0.010 |
GeneticVariation
|
BEFREE |
This suggests CEBPE regulates a similar set of genes in each, consistent with a common biological mechanism of leukemogenesis for rs2239630 associated and CEBPE translocated ALL.
|
29977016 |
2019 |
|
rs25487
|
|
Leukemogenesis
|
|
0.010 |
GeneticVariation
|
BEFREE |
These data suggest that XRCC1 Gln399Arg polymorphism plays a limited role in lymphomagenesis.
|
15104288 |
2004 |
|
rs267601394
|
|
Leukemogenesis
|
|
0.010 |
GeneticVariation
|
BEFREE |
In summary, EZH2(Y641F) can collaborate with Myc to accelerate lymphomagenesis demonstrating a cooperative role of EZH2 mutations in oncogenesis.
|
24802772 |
2014 |
|
rs371769427
|
|
Leukemogenesis
|
|
0.010 |
GeneticVariation
|
BEFREE |
In an attempt to identify <i>U2af1</i>(S34F)-cooperating changes that promote leukemogenesis, we combined <i>U2af1</i>(S34F) with <i>Runx1</i> deficiency in mice and further treated the mice with a mutagen, <i>N</i>-ethyl-<i>N</i>-nitrosourea (ENU).
|
30322915 |
2018 |
|
rs373667881
|
|
Leukemogenesis
|
|
0.010 |
GeneticVariation
|
BEFREE |
This R107L mutation remained in leukocytes of the remission stage in which GATA1 mutation disappeared, suggesting the TRIB1 mutation is an earlier genetic event in leukemogenesis.
|
22294728 |
2012 |
|
rs377577594
|
|
Leukemogenesis
|
|
0.010 |
GeneticVariation
|
BEFREE |
Molecularly, both DNMT3A-WT and R882H/C mutants interacted with PRDX2; and R882C/H mutation-induced hypomethylation increased PRDX2 expression which enhanced cell proliferation and growth with impairment of apoptosis, thereby contributing to leukemogenesis.
|
30245403 |
2018 |
|
rs397507510
|
|
Leukemogenesis
|
|
0.010 |
GeneticVariation
|
BEFREE |
We identified TET2 and PTPN11 mutations in both mouse and human AML and then demonstrated the ability of Tet2 loss and PTPN11 D61Y to initiate leukemogenesis in concert with expression of AML1-ETO in vivo.
|
26666262 |
2016 |
|
rs568887534
|
|
Leukemogenesis
|
|
0.010 |
GeneticVariation
|
BEFREE |
In contrast, p27 mutations that enhance its stability (p27(T187A)) or nuclear retention (p27(S10A)) attenuate leukemogenesis over wild-type p27, validating the tumor-suppressor function of nuclear p27 in CML.
|
25293778 |
2014 |
|
rs757412228
|
|
Leukemogenesis
|
|
0.010 |
GeneticVariation
|
BEFREE |
We identified TET2 and PTPN11 mutations in both mouse and human AML and then demonstrated the ability of Tet2 loss and PTPN11 D61Y to initiate leukemogenesis in concert with expression of AML1-ETO in vivo.
|
26666262 |
2016 |